|
|
|
<:Back
|
|
Improving Access to Essential Health Technologies: Focusing on Neglected Diseases, Reaching Neglected Populations
1-2 February 2007 Bangkok, Thailand
|
1. |
Background |
|
The Prince Mahidol Award Foundation was established in commemoration of the Centenary Birthday Anniversary of His Royal Highness Prince Mahidol of Songkla on 1 January 1992. The foundation is chaired by HRH Princess Maha Chakri Sirindhorn. The Prince Mahidol Award (PMA) was established in honour of HRH’s initiative and efforts that produced a remarkable and lasting impact on the development and improvement of modern medicine and public health in Thailand. HRH was subsequently honoured with the title of "Father of Modern Medicine of Thailand" and "Father of Public Health of Thailand." The Prince Mahidol Award is conferred annually by His Majesty the King of Thailand to individual(s) or institution(s) for outstanding performance and/or research that has a global impact in the field of medicine and public health. The Award was first conferred in 1993 and will achieve its 15th anniversary in 2007.
To celebrate the 15th anniversary of the Award, an international conference focusing on important global health issues that have global impacts will be organized on an annual basis. The Prince Mahidol Award Conference 2007 (PMA Conference 2007) will be held on 1-2 February 2007 under the theme of “Improving Access to Essential Health Technologies: Focusing on Neglected Diseases, Reaching Neglected Populations.”
It is a tragedy that the poor, who are most in need of access to health technologies to prevent disease and restore good health, are the least likely to be able to access these technologies. Bill Gates at the 58th World Health Assembly in 2005 provided several macro political and economic reasons for limited access of the poor to essential medicine:
“… Rich governments are not fighting some of the world’s most deadly diseases because rich countries don’t have them. The private sector is not developing vaccines and medicines for these diseases because developing countries can’t buy them. And many developing countries are not doing nearly enough to improve the health of their own people. … In order to find new discoveries and deliver them, we need to make political and market forces work better for the world’s poorest people.”
According to the Report of the Commission on Intellectual Property Rights, Innovation and Public Health (CIPIH) 2006, the Innovation Cycle encompasses three interrelated phases: the Discovery phase which includes basic research, the Development of the Discovery phase, and the Delivery phase to get the products to patients. How the three phases be of better benefit to those in need, both in developed and developing countries, are the main concern of the PMA Conference 2007. The Conference would address all diseases types. Type I diseases affect both rich and poor countries where Discovery and Development is not a major problem, but Delivery especially to the poor in rich and other developing countries is a real problem. With regards to Type II diseases which are more prevalent in developing countries (the neglected diseases) and Type III diseases which are exclusively prevalent in developing countries (the very neglected diseases), patients in developing countries are facing no Discovery, Discovery but no further Development, and no effective Delivery and secure financing.
Economic and market forces direct vaccine sales and vaccine production towards the needs of markets with effective purchasing power. Yet the scientific and technological progress that drives the Development of such innovative vaccines holds the promise of applicability for vaccines that are urgently needed for developing countries. This results in orphan drugs and vaccines.
While observing intellectual property rights, new mechanisms and incentives for research and development (R&D) of innovations in global public goods is needed to minimize the impact of intellectual property rights and patent protections that might lead to unaffordable prices for new technologies and result in limited access, especially for the poor in developing countries.
Progress is required to ensure that new technologies are affordable and relevant to the needs of developing countries, including their disease patterns and health systems capacity. In addition, mechanisms to secure a sustainable demand for new technology, for example through advance purchase commitments, must be developed.
There is a need to overcome health systems constraints in order to effectively, efficiently, and equitably deliver both existing and new health technologies to the populations most in need of these technologies.
The Prince Mahidol Award Conference 2007 will address issues of accessibility to health technologies in order to bring global attention to this important problem and to suggest actions that would improve health access in order to improve the health of the most vulnerable populations and hence contribute to the achievement of the Millennium Development Goals (MDGs). |
| 2. |
Objective of the PMA Conference |
|
2.1 General objective |
|
To organize an annual Prince Mahidol Award Conference to discuss high priority global health issues and propose solutions that will have a global impact. |
|
2.2 Specific objectives of the PMA Conference |
|
|
1. |
To organize, on an annual basis, an international health conference on priority health issues that are of global significance. |
|
2. |
To promote participation of leading scientists and public health leaders from around the world. |
|
3. |
To organize the Conference based on a systematic and participatory approach that ensures recommendations from the Conference will have a global health impact. |
|
4. |
To provide an opportunity for networking, capacity strengthening and leadership development, among leading scientists, public health leaders and administrators in international public health. |
|
| 3. |
Theme of the PMA Conference 2007 |
|
The theme of the PMA Conference 2007 is “Improving Access to Essential Health Technologies: Focusing on Neglected Diseases, Reaching Neglected Populations.” Health technologies include the full range of techniques/technologies employed in health, such as prevention, diagnostics, medical devices, pharmaceuticals, vaccines, biotechnology and traditional medicine and other public health interventions. Promoting access to essential health technologies requires that five questions be addressed. Are essential health technologies
available? If yes, are they accessible to people who need them? Are they
affordable, especially by the poor, who need them? Are the health technologies
effective and of good quality? And, the most important question,
HOW can essential health technologies be made accessible to those who need them most. This would include the health care systems to deliver the essential health technologies. |
| 4. |
Agenda of the PMA Conference 2007 |
|
Based on the main theme and questions raised above, the Conference will organize sessions based on the three Ds of the Innovation Cycle to draw lessons learned and bring out recommendations from the case studies. The main objectives of each session are as follows: |
|
4.1 Keynote speeches |
|
Topic: Access to essential health technologies: global perspective
Keynote
speakers are those who are very provocative and are global public health leaders, or global political leaders. The main purpose of this session is to set the scene of the whole issue on a global perspective, past achievements and limitations, the unfinished agenda, future challenges, and the way forward, including challenging questions to be addressed by this Conference. Suggested solutions to the problems are welcome.
|
|
4.2 Panel discussions |
|
There will be two panel discussions. Each panel discussion consists of no more than 3-4 speakers with geographical and gender balance. The objectives are to provide states of the arts in the subject matter, provoke further in-depth discussions (in parallel sessions) on the problems and issues, and most importantly, provide practical solutions to these problems.
Panel discussion 1
Topic: From Discovery to Development to Delivery of health technology – challenges and lessons learned
The objective of this session is to provide global experiences on both successes and limitations from discovery of sciences to developments and delivery of these products, especially to the neediest population and for the benefit of mankind. The topics cover the wide range of prevention, screening, diagnostics and curatives, including medicines and vaccines.
Panel discussion 2
Topic: The way forward: Immediate actions to stimulate Discovery, Development and improved access to essential health technology
The objective is to provide summary reports extracted from all the parallel sessions on problems and issues, and special focus on the practical solutions in line with the CIPIH report. In the context of the ongoing deliberations of the Inter-Governmental Working Group to discuss and propose global strategies and action plans, members of the CIPIH and IGWG would provide their comments in this panel. |
|
4.3 Parallel sessions |
|
The objectives of parallel sessions are to allow a maximum and in-depth deliberation by conference participants on the specific subject matter. The chairperson will ensure clear and straight-to-the-point presentation and provide ample time for discussion by participants.
The panelists and participants in each parallel session are urged to not only focus on bottlenecks but also propose practical and succinct solutions in line with the CIPIH report.
In addition, panelists would be invited on their individual expertise and capacity, and do not reflect the position of their institution.
There will be seven parallel sessions in this Conference.
Parallel session 1.1
Topic: From Discovery to Development: the cases of neglected diseases
The objectives are to discuss the bottlenecks between discovery in laboratory and a thorough understanding of science and the development of products on a commercial scale for neglected diseases. Panelists are urged to cover the whole range of prevention technologies, diagnostic technologies, vaccines and medicines for these neglected diseases. This session covers several neglected diseases, not only pinpointing one particular disease.
The discussion on these bottlenecks or other success stories would lead to tangible recommendations in line with the CIPIH report.
Parallel session 1.2
Topic: The emerging roles of scientifically and technologically advanced developing countries in Discovery and Development of essential health technologies and the role of productions of generic products
The objective is to describe, analyze the experiences on the emerging roles of scientifically and technologically advanced developing countries in discovery and development of essential health technologies, and cover the role of productions of generic products to be more affordable and accessible by the poorer countries. Experiences include the enabling government policy, science capacity in the public and private sectors, as well as public-private partnership experiences. This parallel session is the most tangible recommendation for the CIPIH.
Parallel session 1.3
Topic: Product development partnership on Discovery and Development of health technologies
The objective is to provide experiences on the Partnership (in particular on product development, not much on the discovery and delivery) which would include not only public-private partnerships, but also North-South and South-South collaborations.
Parallel session 2.1
Topic: From Discovery to Development and to Delivery of essential health technologies: the role of Innovative Financing Mechanisms
The objective is to describe and analyze the experiences on innovative financing mechanisms that enable the Discovery, the Development and the Delivery of health technologies. Efforts should be solicited from both global health initiatives and developing country perspectives.
Parallel session 2.2
Topic: TRIPS flexibility and access to medicine, the case of new ARV medicines
The objective is to describe and analyze experiences, government policies, and relationships with NGOs as well as the institutional capacity on the application of TRIPS flexibilities to protect the public health interests of the population, limitations and other major bottlenecks for the implementation of the Doha Declaration. This parallel session is requested to use the tracer of ARV medicine, including new 1st line and 2nd line patent ARV, as sample for discussion.
Parallel session 3.1
Topic: From Development to Delivery: the case of access to HPV vaccine for prevention of cervical cancer
The objective is to address the downstream delivery aspect of new technologies. This session applies HPV vaccine as a tracer to illustrate how a country would introduce this technology. Issues would include for example, burden of disease, licensing of product, cost effectiveness, cost and pricing, national health financing policy including health insurance mechanism, and health systems capacity to scaling up sustainable and equitable access to intervention.
Parallel session 3.2
Topic: From Development to Delivery: access to prevention, screening, diagnostics and treatments for noncommunicable diseases (e.g. diabetes mellitus, hypertension, cancers)
The objective is to describe and analyze the health systems capacity for early detection, screening, diagnosis, prevention and effective control of these diseases. Health systems capacity is vital to cope with long-term treatment of these chronic diseases.
Presentation and discussion would include pricing and financing, including the role of national health insurance systems, availability of affordable technologies for primary prevention, social franchising, roles of pharmacists and refilling medication. The session requires novel solutions, not only voicing the problems. Presenters should have a thorough understanding of the health systems role.
|
|
4.4 Conclusion session |
|
Conference wrap up, synthesis and recommendations |
| 5. |
Program of the PMA Conference 2007 |
|
| Feb 1, 2007 |
|
09.00-09.15 |
Opening session
HRH Princess Maha Chakri Sirindhorn
|
|
09.15-10.15 |
Keynote speeches
Access to essential health technologies: global perspective
Dr. Margaret Chan (Director-General, WHO) Confirmed
Dr. Stanley G. Schultz (PMA Awardee 2006) Confirmed
Dr. Dilip Mahalanabis (PMA Awardee 2006) Confirmed
|
|
10.15-10.30 |
Break
|
|
10.30-12.30 |
Panel discussion 1
From Discovery to Development to Delivery of health technology – challenges and lessons learned
Prevention interventions
Prof. Harald zur Hausen (PMA Awardee): Infectious agents in human leukaemias and lymphomas Confirmed
Curative interventions
Sir Richard Peto (PMA Awardee 2000): Tamoxifen chemotherapy and breast cancer Confirmed
Delivery
Prof. Nicholas White (Wellcome Trust Unit, Faculty of Tropical Medicine, Mahidol University) Confirmed
Dr. P. Roy Vagelos (PMA Awardee) Confirmed
Chairperson: Dr. Omi Shigeru (WHO/WPRO Regional Director) TBC
Rapporteur: TBD: Joint rapporteurs from International and Thai organizing committee members
|
|
09.15-10.15 |
Keynote speeches
Access to essential health technologies: global perspective
Dr. Margaret Chan (Director-General, WHO) Confirmed
Dr. Stanley G. Schultz (PMA Awardee 2006) Confirmed
Dr. Dilip Mahalanabis (PMA Awardee 2006) Confirmed
|
|
10.15-10.30 |
Break
|
|
09.00-09.15 |
Opening session
HRH Princess Maha Chakri Sirindhorn
|
|
12.30-14.00 |
Lunch
|
|
14.00-16.00 |
Parallel session 1 Note: Panelists will focus on bottlenecks and practical solutions in line with the CIPIH report. Panelists would be invited on their individual expertise and capacity, and do not reflect the position of their institution.
|
|
|
Parallel session 1.1
From Discovery to Development: the cases of neglected diseases
Panelists are invited to provide perspectives on problems encountered and possible solutions.
Dr. Giorgio Rosigno (Executive Director, Foundation for Innovative New Diagnostics): TB diagnostics Confirmed
Dr. Paul Herrling (Head of Corporate Research, Novartis) Confirmed
Dr. Olivier Fontaine (Child and Adolescent Health and Development, WHO): Zinc therapy for diarrhea Confirmed
Prof. Joanne Webster (Acting Director of SCI, Imperial College) Confirmed
Discussion and recommendations
Chairperson: Dr. Howard Zucker (Assistant Director-General, WHO) TBC
Rapporteur: TBD: Joint rapporteurs from International and Thai organizing committee members |
|
|
Parallel session 1.2
The emerging roles of scientifically and technologically advanced developing countries in Discovery and Development of essential health technologies and the role of productions of generic products
Perspectives from:
Dr. Hans Hogerzeil (Director, Medicines Policy and Standards, WHO): Pre-qualification schemes (past, present and future) Confirmed
Dr. K. Monique Wasunna (Director, Center for Clinical Research, Kenya Medical Research Institute) TBC
Dr. Shao Yiming (Chief expert on AIDS, Chinese Center for Disease Control and Prevention) Confirmed
Discussion and recommendations
Chairperson: Dr. Richard Nesbit (DPM, WHO/WPRO) TBC
Rapporteur: Dr. Eamonn Murphy (Director – Governance, Donor and UN System Relations,
UNAIDS) TBC
|
|
|
Parallel session 1.3
Product development partnership (public-private, North-South, South-South collaborations) on Discovery and Development of health technologies
Perspectives from (with special focus on practical problems and solutions in line with the CIPIH report):
Dr. Javier Guzman (Head Sydney Research Team, Pharmaceutical R&D Policy Project, The George Institute for International Health) Confirmed
Dr. P V Venugopal (Director of International Operations, Malaria Medicine Venture) Confirmed
Dr. John Wecker (Director, Immunization Program, PATH): Rota TBC
Dr. Bernard Pecoul (Director, Drugs for Neglected Diseases initiative) Confirmed
Discussion and recommendations
Chairperson: Dr. Myint Htwe (DPM, WHO/SEARO) TBC
Rapporteur: TBD: Joint rapporteurs from International and Thai organizing committee members
|
|
16.00-16.30 |
Break
|
|
16.30-17.30 |
Presentation of major findings and recommendations from the parallel sessions 1.1-1.3
|
|
18.30-20.30 |
Reception / dinner |
| Feb 2, 2007 |
|
08.30-10.30
|
Parallel session 2
Parallel session 2.1
From Discovery to Development and to Delivery of essential health technologies: the role of Innovative Financing Mechanisms (Note: Focus on global health initiatives and developing country experiences)
Perspectives from:
Dr. Philippe Duneton (Interim Executive Director, UNITAID): International Drug Purchase Facility Confirmed
Prof. Sulamis Dain (Professor of Public Health, State University of Rio de Janeiro, Brazil): Tobin Tax Confirmed
Dr. Tim Hubbard (Head of Human Genome Analysis, Wellcome Trust Sanger Institute): R&D Treaty Confirmed
Dr. Jacques Baudouy (Director Health, Nutrition and Population, The World Bank) Advance Market Commitment Confirmed
Rep. from DFID
Chairperson: Dr. Ellen T. Hoen (Director Policy Advocacy, MSF) TBC
Rapporteur: Mr. James Arkinstall (MSF) and Thai organizing committee members TBC
|
|
|
Parallel session 2.2
TRIPS flexibility and access to medicine, the case of new ARV medicines (including new 1st line and 2nd line patent ARV)
Experiences from:
Dr. Carlos Correa (Member of CIPIH, U of Buenos Aires): Overview of TRIPS flexibilities, including Article 7 of TRIPS Confirmed
Dr. Martin Khor (Director of the Third World Network): Compulsory licensing and Parallel Importation experiences in developing countries and the applications of the Doha Declaration Confirmed
Dr. Brigitte Zirger (Director of Policy, Therapeutic Products Division, Health Canada): Developed country experiences in the amendment of Patent Law to support the Doha Declaration TBC
Dr. Harvey Bale (Director-General, International Federation of
Pharmaceutical Manufacturers & Associations): USA FTA on TRIPS Plus Confirmed
Discussion and recommendations on experiences to cope with TRIPS, TRIPS Plus and the implementation experiences of the Doha Declaration
Chairperson: Dr. F. Antezana Aranibar (Senior Advisor, Ministry of Health, Bolivia) TBCan>
Rapporteur: Ms. Cecilia Oh Mei-Yun (UNDP Regional Centre in Colombo) and Dr. Jiraporn
Limpananont (Chulalongkorn University) TBC pan> |
|
10.30-11.00 |
Break
|
|
11.00-13.30 |
Parallel session 3
Parallel session 3.1
From Development to Delivery: the case of access to HPV vaccine for prevention of cervical cancer
Perspectives from:
Dr. Jean-Marie Okwo-Bele (Director, Immunization, Vaccines and Biologicals Department, WHO): Reproductive health program Confirmed
Dr. Hugues Bogaerts (Vice President, Ww Medical Affairs Cervarix, GlaxoSmithKline Biologicals Clinical R&D): Tier pricing policies Confirmed
Prof. Emeritus Khunying Kobchitt Limpaphayom (Chulalongkorn University) Confirmed
Dr. Julian Lob-Levyt (Executive Secretary, Global Alliance on Vaccine and Immunization, United Kingdom) Confirmed
Discussion and recommendations on Delivery of expensive new technologies
Chairperson: Prof. Goran Tomson (Department of Public Health Sciences, Karolinska Institute, Sweden) TBC
Rapporteur: TBD: Joint rapporteurs from International and Thai organizing committee members
|
|
|
Parallel session 3.2
From Development to Delivery: access to prevention, screening, diagnostics and treatments for non-communicable diseases (e.g. diabetes, hypertension, cancer)
Perspectives from:
Dr. Robert Beaglehole (WHO) TBC
o Developed country perspectives:
- Dr. Stephen Leeder (University of Sydney, Australia) Confirmed
Developing country perspectives:
- Prof. Srinath Reddy (Professor of Cardiology, All India Institute of Medical Sciences, India) Confirmed
- Dr. Sania Nishtar (Founder and President, Heartfile, Pakistan) Confirmed
Discussion and recommendations on Delivery of interventions for non-communicable diseases
Chairperson: Dr. Lincoln Chen TBC
Rapporteur: TBD: Joint rapporteurs from International and Thai organizing committee members
|
|
13.30-14.30 |
Lunch
|
|
14.30-15.30 |
Panel discussion 2
The way forward: Immediate actions to stimulate Discovery, Development and improved access to essential health technology
Summary reports from the seven parallel sessions on practical solutions, within the scope of the CIPIH recommendations by representative of the Drafting Group
Comments and perspectives from:
Dr. Pakdee Pothisiri (Member of CIPIH) Confirmed
Dr. David Nabarro (UNDP) Confirmed
Dr. A.E.O. Ogwell (Assistant Director of Medical Services and Head, International Health Relations, Ministry of Health, Kenya) Confirmed
Dr. Kimmo Leppo (Director General, Ministry of Social Affairs and Health, Finland) TBC
General discussion
Chairperson: Prof. Dr. Vicharn Panich, Chairman of the Conference Organizing Committee
Rapporteur: TBD: Joint rapporteurs from International and Thai organizing committee members
|
|
15.30-16.00 |
Break
|
|
16.00-17.00 |
Conference wrap up, synthesis and recommendations Chairperson: Prof. Dr. Vicharn Panich, Chairman of the Conference Organizing Committee Rapporteur: TBD
|
|
17.00-17.30 |
Closing session
Dr. Samlee Pliangbangchang, Regional Director, WHO/SEARO TBC
Minister of Public Health TBCan>
|
|
17.30-18.00 |
Press conference
Prof. Dr. Vicharn Panich, Chairman of the Conference Organizing Committee
Dr. Howard Zucker, Co-Chairman of the Conference Organizing Committee
Ministry of Public Health
|
|
|
|
6. |
Proposed theme and programs of the PMA Conference 2008 |
|
1. |
Taking into account the context of the ongoing Inter-Governmental Working Group (IGWG) on CIPIH that would possibly convene its first meeting in December 2006 and shall report a global strategy and action plan to the 60th WHA in May 2007 and the 61st WHA through EB, the PMA Conference would have two opportunities in February 2007 and 2008 to conduct a synergistic theme on CIPIH in order to provide its recommendations as input to the IGWG processes, or through members and observers in the IGWG. |
|
2. |
The theme for the PMA Conference 2008 would be in tune with the results discussed in the 60th WHA in May 2007, whereby several work sessions could be conducted in association with the IGWG. The Conference organizing committee will meet around June 2007. |
|
3. |
3. February 3, 2007 is scheduled for the organizing committee for face to face meeting in order to draw lessons from the first PMA Conference. Perhaps the organizing committee members may attend the first IGWG in December and the Thai Mission and WHO HQ in GVA may host the organizing committee meeting after the IGWG met. |
|
7. |
Conference outputs |
|
1. |
Recommendations for improvements in accessibility of essential health technologies in developing countries. |
|
2. |
Concrete action plan for further steps. |
|
8. |
Conference partners |
|
|
The Conference will be organized by the Prince Mahidol Award Foundation in collaboration with the World Health Organization and other partners, including UNAIDS, GAVI, private foundations, private industries and civil society organizations. Other partners involved in the organization of the Conference are the Gates Foundation and the World Bank. |
|
9. |
Conference participants |
|
|
A total of approximately 150-200 participants will be invited to attend the Conference, with some limited number of participants who are interested to attend based on the criteria set by Organizing Committee. Participants will be balanced between different groups as follows: |
|
|
| Type of Organization |
Name of Organization |
Suggested Name |
|
UN/Inter-Governmental Working Group |
|
WHO |
DG, RD SEAR, RD WPRO, Howard Zucker, Lorenzo Savioli |
|
World Bank |
Jacques Baudouy |
|
UNAIDS |
Prasadra Rao, Eamonn Murphy |
|
UNAI group |
David Nabarro |
|
World Trade Organization |
|
|
WIPO |
Sherif Saadallah |
|
ILO |
Tsuyoshi Kawakami |
|
UNICEF |
Peter Salama |
|
UNDP |
Cecilia Oh |
|
|
Global Health Partners |
|
GAVI |
Julian Rob Levit |
|
Stop TB |
|
|
Roll Back Malaria |
|
|
GHWA |
Francis Omazawa |
|
Health Metrics Network |
Carla Abou-Zahr |
|
MCH |
|
|
IAVI |
|
|
TDR |
Robert Ridley |
|
|
N. NGOs |
|
MSF |
Ellen T. Hoen, David W. Wilson, James Arkinstall |
|
CPtech |
James Love |
|
HAI |
Graham Dukes |
|
Save the Children Fund |
|
|
OXAM |
|
|
|
Global Health Partners |
|
GAVI |
Julian Rob Levit |
|
Stop TB |
|
|
Roll Back Malaria |
|
|
GHWA |
Francis Omazawa |
|
Health Metrics Network |
Carla Abou-Zahr |
|
MCH |
|
|
IAVI |
|
|
TDR |
Robert Ridley |
|
|
N. NGOs |
|
MSF |
Ellen T. Hoen, David W. Wilson, James Arkinstall |
|
CPtech |
James Love |
|
HAI |
Graham Dukes |
|
Save the Children Fund |
|
|
OXAM |
|
|
|
Global Health Partners |
|
GAVI |
Julian Rob Levit |
|
Stop TB |
|
|
Roll Back Malaria |
|
|
GHWA |
Francis Omazawa |
|
Health Metrics Network |
Carla Abou-Zahr |
|
MCH |
|
|
IAVI |
|
|
TDR |
Robert Ridley |
|
|
N. NGOs |
|
MSF |
Ellen T. Hoen, David W. Wilson, James Arkinstall |
|
CPtech |
James Love |
|
HAI |
Graham Dukes |
|
Save the Children Fund |
|
|
OXAM |
|
|
|
S. NGOs |
|
People Health Assembly |
Hani Serag, Prem Chandran John |
|
TWN |
Chee Yoke Ling |
|
NCAIDs |
Shao Yiming |
|
Intellectual Property Left |
Nam Hee Sob |
|
EPN |
Albert Petersen |
|
|
Inter-Governmental Working Group on CIPIH |
2 countries from
6 WHO regions |
|
Development partners |
|
USAID |
Richard Greene |
|
DFID |
Stewart Tyson |
|
Norad |
Sigrun Mogedal |
|
SIDA |
Goran Tomson |
|
CIDA |
Stephen McGurk |
|
JICA |
Sadako Ogata |
|
Danida |
|
|
AusAID |
|
|
France |
|
|
Italy |
|
|
|
Inter-Governmental Working Group on CIPIH |
2 countries from
6 WHO regions |
|
Development partners |
|
USAID |
Richard Greene |
|
DFID |
Stewart Tyson |
|
Norad |
Sigrun Mogedal |
|
SIDA |
Goran Tomson |
|
CIDA |
Stephen McGurk |
|
JICA |
Sadako Ogata |
|
Danida |
|
|
AusAID |
|
|
France |
|
|
Italy |
|
|
|
Regional partners |
|
APEC Secretariat |
Ambassador Tran Trong Toan |
|
APEC Task Force |
Bersabel Ephrem |
|
ASEAN |
H.E. Ong Keng Yong |
|
BIMST-EC |
|
|
HIV/AIDS Technical Network |
Cristina d’Almeida |
|
SAARC |
H.E. Mr. Chenkyab Dorji |
|
ASEAN Foundation |
|
|
ASEM |
|
|
|
Industries (R&D; Generic Manufacture, Transnational Pharmaceutical; the medical equipments group) |
|
IFPMA |
Harvey Bale |
|
PhRMA |
Geralyn Ritter |
|
EFPIA |
Brian Ager |
|
National Chamber of Generic Products |
Roman Macaya |
|
|
Foundations |
|
GATES |
David Fleming |
|
RF |
Katherine Bond, Jacob Werksman |
|
Wellcome Trust |
Tim Hubbard |
|
NTI |
|
|
CMB |
Lincoln Chen |
|
Clinton Foundation |
Chuckra Chai, Aaron Pattillo |
|
|
Academics and research institutes |
|
NIH |
Surapol Issarakraisorn |
|
Geneva University Hospital |
Slim Slama |
|
National Institute of Immunology |
Ranjit Roy Chaudhury |
|
College of Public Health, Chulalongkorn University |
Chitr Sitthi-amorn |
|
Makerere University, Uganda |
Margaret M.K. Muganwa |
|
University of Liverpool |
David Molyneux |
|
University of New Castle |
David Henry |
|
Yale |
|
|
MIT |
|
|
NIAID |
|
|
Fogarty Foundation |
|
|
|
Developing countries |
|
|
Communities affected by diseases |
|
|
Thai institutes |
|
Ministry of Public Health |
|
|
National Health Foundation |
Dr. Somsak Chunharat |
|
Research Institute of Health Science |
Dr. Theera Sirisanthana,
Dr. Suwat Chariyalertsak |
|
|
MoPH of countries having problems related to set topics |
|
|
Others |
|
Task Force for Child Survival and Development |
Nana A. Y. Twum-Danso |
|
International Trachoma Initiative |
Jacob Kumaresan |
|
|
|
10. |
Conference location |
|
|
The Conference will take place at the Imperial Queen’s Park Hotel, Bangkok, Thailand. |
|
11. |
Conference costs |
|
|
Core funding for the Conference cost is provided mainly by the Royal Thai
Government with partial support from all the co-host organizations. |
|
|
|
|
